Xeris Biopharma Holdings, Inc. XERS Short- and long-term operating lease liabilities

Short- and long-term operating lease liabilities at other companies

Oruka Therapeutics, Inc.ORKA

-$125K-495%

Rumble, Inc.RUM

-$337.78K-40.4%

Mission Produce, Inc.AVO

-$2.8M-3.7%

The Baldwin Insurance Group, Inc.BWIN

-$4.74M-16.2%

NextNavNN

$77K-63.7%

Target HospitalityTH

-$2.3M-33.9%

Other financials

Income statement

See full

Revenue$83.1M+38.3%

Gross profit$72.6M+41.2%

Operating income$7.9M+356%

Net income$2.2M+124%

EPS (diluted)$0.01+117%

Balance sheet

See full

Cash & equivalents$111.8M+91.2%

Total debt$258.6M-3.8%

Total equity$13.0M+137%

Total assets$392.0M+24.3%

Cash flow

See full

Operating cash flow$9.9M+198%

CapEx$131.0K—

Free cash flow-$29.1M—

Valuation

See full

Market cap$1.28B+76.9%

Enterprise value$1.42B+52.7%

P/E106.4×—

P/S4.1×+0.8×

Profitability

See full

Gross margin85.9%+3.7pp

Operating margin11.4%+7.7pp

Net margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-209.8%—

Debt / equity19.9×—

Current ratio2.1×+0.4×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xeris Biopharma Holdings, Inc.'s short- and long-term operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Xeris Biopharma Holdings, Inc.'s short- and long-term operating lease liabilities?: Xeris Biopharma Holdings, Inc. (XERS) reported short- and long-term operating lease liabilities of -$434K in Q1 2026.
How has Xeris Biopharma Holdings, Inc.'s short- and long-term operating lease liabilities changed year-over-year?: Xeris Biopharma Holdings, Inc.'s short- and long-term operating lease liabilities decreased by 23.3% year-over-year, from -$352K to -$434K.